Edwards Lifesciences (EW) 4: Lippis Daniel J. bought 1,019 shares of Common Stock at $59… (Jan 9, 2026)

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-01-09 10b5-1 Pre-arranged Plan: Yes --- Issuer --- Name: Edwards Lifesciences Corp (EW) CIK: 0001099800 --- Reporting Owner --- Name: Lippis Daniel J. CIK: 0002004380 Role: Officer (CVP, TAVR) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-01-09 | Code: M (Exercise of derivative) Shares: +1,019 | Price: $59.26 Total Value: $60,382.58 Shares Owned After: 23,020.9103 | Ownership: D (Direct) Footnotes: [F1] The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. [Transaction #2] Security: Common Stock Date: 2026-01-09 | Code: S (Open market sale) Shares: -1,019 | Price: $85.70 Total Value: $87,332.07 Shares Owned After: 22,001.9103 | Ownership: D (Direct) Footnotes: [F1] The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. [F2] This transaction was executed in multiple trades at prices ranging from $85.45 to $85.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of theIssuer, full information regarding the number of shares and prices at which the transaction was effected. --- Derivative Transactions --- [Transaction #1] Security: Employee Stock Option (Right to Acquire) Date: 2026-01-09 | Code: M (Exercise of derivative) Shares: -1,019 | Price: $0.00 Exercisable: N/A | Expires: 2026-05-07 Shares Owned After: 4,076 | Ownership: D (Direct) --- Footnotes (Complete Index) --- F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F2: This transaction was executed in multiple trades at prices ranging from $85.45 to $85.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of theIssuer, full information regarding the number of shares and prices at which the transaction was effected. --- Signature --- /s/ Linda J. Park, Attorney-in-Fact (2026-01-09)